Company Overview
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +201.37% |
| 6 Months: | +12.18% |
| 3 Months: | -7.69% |
| 1 Month: | +28.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.14 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TYRA Tyra Biosciences, Inc. R2K | 32.88 | -15.08 | $1.96B | 0.00% | -50.19% | -36.87% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -2.33M | - | -4.21M | -5.51M | -6.64M | -14.83M | -15.43M | -13.64M | -14.33M | -16.01M | -23.96M | -22.32M | -23.53M | -28.60M | -31.85M | -31.45M | -32.94M | -42.00M |
| Net Income | -1.47M | -1.84M | -2.34M | -3.69M | -4.21M | -5.51M | -6.64M | -14.83M | -15.10M | -12.51M | -11.88M | -13.27M | -21.15M | -18.19M | -18.70M | -24.02M | -28.15M | -28.10M | -29.87M | -39.30M |
| Diluted EPS | - | - | - | - | - | -2.43 | -0.72 | -0.36 | -0.36 | -0.30 | -0.28 | -0.31 | -0.49 | -0.35 | -0.32 | -0.41 | -0.47 | -0.47 | -0.50 | -0.64 |
| R&D Expense | - | - | 1.86M | - | 3.52M | 4.38M | 5.48M | 9.64M | 12.05M | 10.91M | 10.41M | 12.16M | 19.27M | 17.20M | 18.00M | 22.70M | 24.96M | 24.31M | 25.47M | 33.47M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -9.30M | -26.29M | -58.93M | -79.94M | -104.18M | -132.76M |
| Net Income | -9.34M | -26.29M | -55.33M | -69.13M | -86.48M | -119.95M |
| Diluted EPS | - | -1.91 | -1.32 | -1.62 | -1.51 | -2.01 |
| R&D Expense | 7.20M | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.01M | 306.70M | 266.18M | 225.86M | 363.56M | 282.61M |
| Total Equity | -4.74M | -13.64M | 301.74M | 257.83M | 204.26M | 343.15M | 259.18M |
| Cash & Equivalents | - | 15.22M | 302.18M | 251.21M | 58.01M | 91.97M | 77.39M |
| Total Liabilities | - | 2.00M | 4.96M | 8.35M | 21.59M | 20.41M | 23.43M |
| Current Liabilities | - | 1.86M | 3.62M | 5.70M | 15.33M | 14.59M | 18.09M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.76M | -23.75M | -50.28M | -50.14M | -69.77M | -95.14M |
| Investing Cash Flow | -312.00K | -645.00K | -559.00K | -144.60M | -98.40M | 72.46M |
| Financing Cash Flow | 23.43M | 311.35M | 632.00K | 1.54M | 202.14M | 8.10M |
| Capital Expenditure | -312.00K | -661.00K | -559.00K | -770.00K | -664.00K | -141.00K |
| Free Cash Flow | -8.07M | -24.41M | -50.84M | -50.91M | -70.44M | -95.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 68.5% | -8.7% | -21.5% | -33.8% | -25.2% | -46.3% |
| ROCE % | -65.7% | -8.7% | -22.6% | -38.0% | -29.9% | -50.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 20.51% | 12.20M | $374.50M |
| 2 | FMR, LLC | 13.03% | 7.75M | $237.85M |
| 3 | Nextech Invest, Ltd. | 6.82% | 4.06M | $124.51M |
| 4 | Janus Henderson Group PLC | 6.54% | 3.89M | $119.44M |
| 5 | Alta Partners Management Company, L.P. | 6.43% | 3.82M | $117.38M |
| 6 | Farallon Capital Management LLC | 6.02% | 3.58M | $109.93M |
| 7 | TCG Crossover Management, LLC | 5.46% | 3.25M | $99.74M |
| 8 | Commodore Capital Lp | 4.16% | 2.48M | $75.98M |
| 9 | Blackrock Inc. | 3.73% | 2.22M | $68.09M |
| 10 | Paradigm Biocapital Advisors LP | 3.46% | 2.05M | $63.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TYRA
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxQV1AxRlpPMTRJTWtJRWZKdzFlczhNOTYxX3hGRFdoVHViZjJYNjVDbEFHZjRIcHJTSUJWNkU3N19qc0JVZVlGenZ6Q1R0MmJmMWlxQWRENWQ4R0k3RDBHQklyTW5uZW5aalFRSGhubFJDRTNoM21hWDJGQVc0MGRxLWV1eUZfUGtvTkI4VG…
Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPaGp5bWVwUlN6NWFLbG5SNF8yWFI2aWhQUzl1emxQOWVfdEJXLVptYVh3cGlFM19waEdRMDZXX2ZsaVl0Yi01UkR6M1hBQUxXc2FHbFNkMHBtQk1WQ3NQVjloM05nWlpRakgwVE1OcC1CQ2tyVVVmd2taTm5hUy1kcS1peUQzTGt6Z1UySU…
Behavioral Patterns of TYRA and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPVmZHdDMzYV9kcVZTUnktbHp0MU84dDlITGpoZk9rWFA3aDFQaG8yMjB0WktyTXNQekF0Q2ZGUDlQVnhocEZnXzQyZ1NzQ0Mxb1ZQSUdpRm1TbXlZOV9iSnB1TEpNQmctRW1UOU5TZTNQWElSTjJfalE5MXBDVjktclFaSjdiYU56UE05Rk…
$TYRA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNTmpfRVB0aGdvT0pWazBUUjlhZF93QW9NZXRiZnZtVWpvZWVNc2h1VjNCbVNvMVhuME9DS2VrazZ4RWx2c2FTX2hBdENpM19nTkpYZDYtZkVKbnVCc2ZZeFloa2V1aUc2SzFyRDFqX29pVGVtcGFndGhNU0huVEZubFNmc3RqMl9Rbk5DLW…
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdWtYVWtYRUpocTZQUnJneFNFeHlmTzNGbzBCc3phZDFoSHJjQXN0R0RXem5iajEwT0VKclRWNGVTbWRsTk5QVWV0ZzNXSm05czNnX3pVb0FuMzJhQ1FsZDdXT3VUT3g4UWxlSGE2TXl2RlZEOUxfUGpWcFRQMGdBbEVub0hEWWFYRWk5bU…
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQelAtVEJ1SWFnVVc0SFk4QnpoOUc5T3Jxcks4X1ZzczNEVlFHYUJKMm1EUE1ZQW91Y1VsdGZUcERTa2ZTUG44eFJqTG1KUEVlRkhTSENFa0JrV2tuOTlwWlJvV1N6eW5uWWRtV0VGQjlCdmlJMW1tSU92ODdvWjUxRlFGVlpLNmpqOHN6Wi…
TYRA — Frequently Asked Questions
What is the current share price of Tyra Biosciences, Inc. (TYRA)?
As of 2026-07-14 21:23 PDT, Tyra Biosciences, Inc. (TYRA) trades at $32.88 on NasdaqGS. Its 52-week range is $10.10 to $39.61.
What is the market capitalisation of TYRA?
Tyra Biosciences, Inc. (TYRA) has a market capitalisation of $1.96B on NasdaqGS.
What is the P/E ratio of TYRA?
TYRA trades at a trailing price-to-earnings (P/E) ratio of -15.08. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.59.
What is the return on equity (ROE) of TYRA?
TYRA has a return on equity (ROE) of -36.87%. Its return on capital employed (ROCE) is -50.19%.
Is TYRA a good stock to buy?
This page provides a data-driven analysis of Tyra Biosciences, Inc. (TYRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.